

## **SWIXX AND ALBIREO INK PAN-CEE AGREEMENT FOR BYLVAY®**

### **SWIXX ANNOUNCEMENT NO. 41**

**November 4<sup>th</sup>, 2021**

**Baar, Switzerland** – Swixx BioPharma AG of Baar, Switzerland announced today the signing of a distribution contract with Albireo Pharma Inc. of Boston, USA and its Swedish affiliate, Albireo AB. Under the agreement, Albireo has appointed Swixx as exclusive distributor to both commercialize and promote Bylvay® (odevixibat) in the EU territories of Bulgaria, Croatia, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Poland, Romania, Slovakia, and Slovenia as well as in the EU accession territories of Serbia and Bosnia & Herzegovina. Albireo received European Marketing Authorization of Bylvay for the treatment of progressive familial intrahepatic cholestasis (PFIC) in patients aged 6 months or older. PFIC is a rare and devastating disorder affecting young children that causes progressive, life-threatening liver disease. In many cases, PFIC leads to cirrhosis and liver failure within the first 10 years of life.

“Bylvay represents new hope for children suffering from PFIC and experiencing pruritis as a consequence of this rare paediatric cholestatic liver disease,” explained Swixx COO, Dr. Dezso Martha. “Until the advent of Bylvay, the only option for these children has been surgery, including biliary diversion surgery (BDS) or liver transplantation. It is an honour for Swixx to be chosen by Albireo to represent this important new medicine across CEE. We will work with a sense of urgency to make Bylvay available as broadly as possible to paediatric patients in our region.”

#### **About Swixx**

Swixx operates fully owned subsidiaries across Central and Eastern Europe, Greece and Russia. It is currently opening additional subsidiaries in Belarus, Kazakhstan and Uzbekistan. With over 600 employees and sales exceeding 270M Euros in 2021, Swixx has swiftly evolved into the largest and (still) fastest-growing dedicated agent for biopharma and self-medication innovative companies in CEE. The company has gathered outstanding rare disease, oncology-haematology, specialty and self-medication talent under one roof. For more information, please visit [www.swixxbiopharma.com](http://www.swixxbiopharma.com).

#### **About Albireo**

Albireo Pharma is a rare disease company focused on the development of novel bile acid modulators to treat rare pediatric and adult liver diseases. Albireo’s lead product, Bylvay, was approved by the U.S. FDA as the first drug for the treatment of pruritus in all types of progressive familial intrahepatic cholestasis (PFIC), and it is also being developed to treat other rare pediatric cholestatic liver diseases with Phase 3 trials in Alagille syndrome and biliary atresia, as well as an Open-label Extension (OLE) study for PFIC. In Europe, Bylvay has been approved for the treatment of PFIC and has been submitted for pricing and reimbursement approval. The Company is progressing a Phase 1 clinical trial for A3907 to advance development in adult cholestatic liver disease, with IND-enabling studies moving ahead with A2342 for viral and cholestatic liver disease. Albireo was spun out from AstraZeneca in 2008 and is headquartered in Boston, Massachusetts, with its key operating subsidiary in Gothenburg, Sweden. The Boston Business Journal named Albireo one of the 2019 and 2020 Best Places to Work in Massachusetts. For more information on Albireo, please visit [www.albireopharma.com](http://www.albireopharma.com).

**Contact: Maja Boskovic, Public Affairs Officer, Swixx BioPharma A.G.**

Maja.Boskovic@swixxbiopharma.com Tel: +381 11 4426 321